PHOENIX, January 19, 2021 / PRNewswire / – (OTC: CELZ) Creative Medical Technology Holdings announced positive data and filed a patent application covering the use of ImmCelz® for the prevention and regression of type 1 diabetes.
In a series of experiments using the non-obese diabetic model, administration of ImmCelz® was able to reduce the incidence of diabetes but also reverse diabetes in several mice. Molecular analysis showed that administration of ImmCelz® was associated with increased production of regenerative cytokines such as VEGF, EGF, IGF and HGF, all of which were involved in the regeneration of damaged pancreatic tissues.
“More than 10 years ago, together with my colleagues, we demonstrated our ability to modulate and even regenerate the destruction of pancreatic tissue through various cell therapies1, “ said Thomas Ichim, Ph.D. and co-inventor of the patent. “The ability to induce pancreatic production through autoimmunity through the use of immune-based regenerative technologies is, to my knowledge, an entirely new and promising area to address the problem of type 1 diabetes.”
While numerous approaches have been used to reduce the immunogenicity of pancreatic tissue, the ImmCelz® approach appears to be superior because of its ability to induce a form of “regenerative memory” in which T cells have the ability to repair damaged tissue.
“The data released today supports the possibility that ImmCelz® is truly a form of ‘regenerative immunotherapy, ‘” said Dr. Amit Patel, Co-inventor of the patent. “To the best of my knowledge, this is the first cell therapy in which immune cells, especially T cells, are programmed by coculture with umbilical cord stem cells to create a product that actually induces the production of regenerative cytokines in vivo.”
“The continued influx of positive experimental data supports the belief that ImmCelz® is a promising therapeutic platform capable of meeting many unmet medical needs related to degeneration and inflammation, “said Timothy Warbington, President and CEO of the company. “Our vision is that ImmCelz® will one day be for degenerative diseases what CAR-T cells were for hematology.”
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial biotechnology company specializing in regenerative medicine and stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics, trading OTC under the ticker CELZ. More information about the company can be found at www.creativemedicaltechnology.com.
Forward-Looking Statements
OTC Markets has not reviewed this version and accepts no responsibility for the adequacy or accuracy of this version. This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical studies and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent statements risks and uncertainties. Actual results could differ materially from those currently expected in such statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the commission’s website at www.sec.gov.
Creativemedicaltechnology.com
www.StemSpine.com
www.Caverstem.com
www.Femcelz.com
1 Yin et al. Co-transplantation with xenogenic newborn porcine Sertoli cells significantly prolongs the survival of islet allografts in non-immunosuppressive rats. 2009 Aug 15; 88 (3): 339- 45.
SOURCE Creative Medical Technology Holdings, Inc.
similar links
http://creativemedicaltechnology.com
